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In this issue Yu and coworkers [1] present data on variation
in treatment patterns for severe sepsis using a large cohort of
patients at eight academic medical centers in the USA. This
cohort was described previously by the same authors in a
landmark paper exploring the epidemiology of severe sepsis
[2]. Their new findings are that treatment patterns varied
widely across the eight hospitals, despite the fact that the
hospitals were all teaching centers and all in the same
country. Although those investigators explored associations
between the use of several elements of care and subsequent
hospital mortality, the only significant correlation was that of
delayed antibiotic use with higher mortality – a finding
reported by others [3,4]. This study gives us cause to ponder
a few issues. First, should we be surprised by this variation?
Second, should we be surprised that the variation was
generally not associated with differences in outcome? Third,
do we think this observation still holds? Finally, how can we
use this information going forward?
Variation in the provision of care is well described [5–8].
Variation due to differences in patient case-mix can be
appropriate and represents individually titrated care. Variation
not explained by differences in case-mix is more concerning,
and suggests that some patients are receiving more care
than necessary whereas others receive less. Yu and
coworkers report significant ‘residual’ variation not obviously
explained by differences in case-mix. One might argue over
the rigor with which one can satisfactorily control for case-
mix differences, but we generally concur with the authors’
findings. Whether this variation matters depends on the
effect on outcomes.
There are two broad sets of outcomes – economic and
patient-centered. Generally, more intense care is more
expensive. Although there are instances when ‘more care
sooner’ may offset downstream costs, as suggested recently
with early-goal directed therapy [9], greater use of
interventions usually drives health care costs up. This is an
unwanted outcome unless patient-centered outcomes
improve as a consequence. That Yu and coworkers did not
show differences in patient-centered outcomes can be
explained in several ways. First, the interventions do not
affect outcome. Certainly, there is mounting evidence that
some of the studied interventions, such as application of the
pulmonary artery catheter, have very small effects at best
[10,11]. However, this explanation is insufficient because it is
likely that some of the interventions, given their potent
physiologic effects, have some influence on outcome.
Second, any beneficial effects are offset by unwanted side
effects. For example, better titration of care secondary to
information gained by pulmonary artery catheter use may be
offset by complications of catheter use, such as pulmonary
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There is important variation in the care of critically ill patients. While some of this variability is
appropriate, and represents individually titrated care, residual variation indicates over- and under-use of
precious resources and is clearly concerning. Recent advances in critical care medicine provide “road
maps” to standardize care and use evidence-based medicine to improve patient outcomes. Knowledge
about which therapies to use, and under what circumstances to use them, could form a basis for
measuring the consistency and quality of our care processes. These simple process measures can be
easily incorporated into daily rounds and serve to inform on the quality of our care.
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embolism [11] or bloodstream infection [12,13]. Third,
although interventions have potential benefits, failure to
administer them at the right time to the right patients
obscures any benefit. For example, aggressive resuscitation
in the early phase of severe illness improves patient
outcomes, as with early goal-directed therapy [9], but can
cause harm if used later in the course of illness [14]. Fourth,
the simultaneous study of multiple interventions, used variably
in an uncontrolled manner, precludes isolation of treatment
effects, given the constraints of sample size and analytic
techniques in this particular study. Thus, it appears there is
variation that is unexplained by differences in case-mix and
associated with increased costs, yet there is no obvious gain
in patient-centered outcome.
Might this observation still hold today? The study was
conducted in 1994. In 1994, we knew how to control
infection but other elements of care were highly empiric. At
that time there was no knowledge of the ‘appropriate’ rate of
use of many modalities. Today, we have much better
evidence to direct care of critically ill patients [9,15–20]. For
example, sepsis care involves control of infection, organ
support, and manipulation of the sepsis cascade. Control of
infection is achieved through prompt administration of
antibiotics and surgical drainage when appropriate. Organ
support is more complicated, but better understood when
broken down into its component parts. Let us consider the
case of ‘respiratory organ’ support. Treatment for respiratory
failure includes a trial of noninvasive positive pressure
ventilation before intubation [21]. Once intubated, patients
should have spontaneous breathing trials [22], daily
awakening [19], continuous or frequent subglottic suctioning
[23], H2 blockade [24], and semirecumbent positioning [18].
If the patient develops acute respiratory distress syndrome,
then the tidal volume should be lowered to 6ml/kg [16].
Similarly, cardiovascular support includes early-goal directed
therapy [9], metabolic support includes tight insulin control
[20], and renal support includes avoidance of low-dose
dopamine [25]. Finally, we can now manipulate the sepsis
cascade with drotrecogin alpha (activated) [15] and steroids
[26].
The problem is that it is unclear whether we are adopting this
evidence into practice. Several recent studies have
demonstrated that publication of trial results have no impact
on physician practice, even within the institutions that one
would think are most likely to incorporate new evidence, for
example teaching hospitals and hospitals that participate in
trials [27–30]. In addition, of course, there is a plethora of
information from other fields about the slow diffusion of
evidence to the bedside. For example, despite strong clinical
evidence of the benefits of thrombolytic therapy for
myocardial infarction, it was only slowly accepted into routine
cardiology practice [31]. Thus, the findings of Yu and
coworkers may well still hold today, despite a far clearer
roadmap for optimal sepsis care.
So, what can we do going forward? By measuring rates of
modality use, Yu and colleagues are describing processes.
At the time of the study, we did not know which processes
were best for many elements of care. That has changed. Now
that we know what use is ‘appropriate’, we could measure
compliance with these processes to inform on the quality of
care. Analogous to measuring β-blocker use after myocardial
infarction, we could operationalize simple measures to reflect
the consistency and quality of our organ support and sepsis
management. For example, each day a given patient is on a
ventilator, the following checklist could be reviewed: has the
patient had a spontaneous breathing trial today?; has
sedation been interrupted to allow full wakening?; and is the
head of the bed elevated? A rate of ‘appropriate ventilator
management’ is thus easily calculated by dividing the number
of ‘yes’ days by the total number of ventilator days.
There are a number of advantages of process measures such
as these [32]. One of the most relevant is their simplicity. In
contrast, outcome measures, such as standardized mortality
ratios, require far greater resources and are fraught with
controversy. In part because of their simplicity, the Joint
Commission on Accreditation of Healthcare Organizations
(an independent, not-for-profit organization that sets the
standards by which health care quality is measured in the
USA) will begin to implement process measure based
evaluations of hospitals as soon as 2004 (Pronovost P,
personal communication, April 2003). However, process
measures need not be confined to the ‘judges’ of our care.
We can even adapt these as simple checklists for our rounds
ourselves! Asking the resident each morning, ‘has the patient
had a spontaneous breathing trial in the past 24 hours?’ and
so on, is a big step forward in increasing process
measurement and decreasing variability.
In conclusion, Yu and coworkers have held a mirror to our
practice. They point out the variability that, given the literature
from other fields, we might even have predicted. The
challenge is not to accept this information passively. With
emerging evidence of the ‘right’ way to provide critical care,
we can hope that a mirror to our future care will show us less
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